Intra-individual variability in Dim Light Melatonin Onset in adults with ADHD and delayed sleep phase syndrome

Completed

• Conditions: ADHD; 10012562

• Registration Number: NL-OMON33409
• Lead Sponsor: Parnassia (Den Haag)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2011-08-18
• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

ADHD and delayed sleep phase syndrome has been diagnosed according to regular clinical diagnostic procedures
Age 18-55
Patient/participant is able to read and understand Patient Information
Patient/participant has signed Informed Consent Form
Patient/participant is able and willing to meet follow up appointments for the study

Exclusion Criteria

A-Comorbid disorder (Axis I) that is very severe at intake and that may interfere with need of rapid treatment or with the goals of the study:
Psychosis
Depressive disorder
Anxiety disorder
Current substance abuse or substance dependence (alcohol: more than 2 consumptions per day or for women more than 15 consumptions in total per week or for men more than 21 consumptionsin total per week. Cannabis and hard drugs: exclusion per se)
- Use of the following medications within a month prior to participation to the study: stimulants, anti-depressive medication, melatonin, anti-psychotic medication, clonidine, benzodiazepines, beta-blockers
- symptoms of dementia , anamnestic disorders or other cognitive disorders
- mental retardation
- insufficient fluency in the Dutch language
-shift working (evening or night) or traveling in 2 timezones within two weeks prior to participation to the study

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The DLMO will be compared between adults with ADHD and delayed sleep phase<br /><br>disorder, and healthy volunteers;<br /><br>- specific comparison of variability of the DLMO in saliva on 5 consecutive<br /><br>days;<br /><br>- the rhythm of body skin temperature and the melatonin production in the<br /><br>patients and controls;<br /><br>- results of sleepparameters such as: bed-time, sleep onset, sleep latency,<br /><br>wake-up time, get up time and total sleep duration in hh:mm.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- correlation between individual parameters such as: gender, age, weight,<br /><br>length, subtype ADHD, daylength at time of measurement, DLMO, body skin<br /><br>temperature-curve, severity of ADHD, actigraph data;<br /><br>- actigraph data: among others number of wake bouts, level of activity in least<br /><br>active period, variation in SO/WT-time per day and between different days in<br /><br>research period.</p><br>